Non-invasive estrogen receptor assessment by [F-18]-fluorestradiol(FES)-PET or circulating tumor cells predicts receptor status in patients with metastatic breast cancer

Eisses, B; Angus, L; van der Vegt, B; Sieuwerts, Am; Kraan, J; Martens, Jw; Glaudemans, Aw; Brouwers, Ah; Hoekstra, Os; Oyen, W; Emmering, J; Gerritse, S; van Oordt, Cwm; Boon, E; van Herpen, Cm; Jager, A; Sleijfer, S; de Vries, Eg; Schroder, Cp